Used in research settings as a potent and selective inhibitor of the menin-MLL (mixed lineage leukemia) protein-protein interaction, making it a valuable tool compound in studies targeting MLL-rearranged leukemia. It demonstrates strong anti-leukemic activity in cell-based assays by disrupting oncogenic gene expression driven by MLL fusion proteins. Due to its specificity and cellular permeability, it is employed in preclinical investigations to validate menin-MLL inhibition as a therapeutic strategy, particularly in acute leukemias with MLL rearrangements. Its application supports the development of targeted cancer therapies and helps elucidate the biological role of menin in leukemia progression.